Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations

The 2018 ESC/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ

(2019) Terry McCormack et al.   EUROPEAN HEART JOURNAL

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

(2018) Meletios Dimopoulos et al.   Journal of Hematology & Oncology

Molecular mechanisms of Carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of Metformin

(2018) Panagiotis Efentakis et al.   BLOOD

A practical review on carfilzomib in multiple myeloma

(2016) Eli Muchtar et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends

(2016) Ramón Vélez et al.   BMJ Open

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

(2014) Ajai Chari et al.   BMC CANCER